Literature DB >> 7992831

Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis.

M C Dal Canto1, M E Gurney.   

Abstract

Transgenic mice expressing mutant Cu,Zn superoxide dismutase (SOD), containing a substitution of glycine at position 93 by alanine, develop disease prevalently affecting motor neurons. Light microscopical and ultrastructural studies reveal that the earliest pathological features are microvesiculation of large neurons of the anterior horns of the spinal cord. These vacuoles originate from dilation of rough endoplasmic reticulum and from degenerating mitochondria. At the end stage of the disease, the microvesicular pattern gives way to atrophic anterior horns showing severe neuronal depletion and hyaline, filamentous inclusions in some of the surviving neurons. Posterior horn neurons and dorsal root ganglia are not affected. With disease progression, moderate degeneration of anterior and lateral columns, severe degeneration of anterior roots, and mild degeneration in posterior columns and roots become apparent. This study shows that a mutation in SOD, known to occur in a percentage of familial amyotrophic lateral sclerosis patients, may affect only selective neuronal populations, although SOD is a ubiquitous enzyme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992831      PMCID: PMC1887498     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse.

Authors:  J P Nowicki; D Duval; H Poignet; B Scatton
Journal:  Eur J Pharmacol       Date:  1991-11-12       Impact factor: 4.432

Review 2.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

3.  Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells.

Authors:  A Hirano; L T Kurland; G P Sayre
Journal:  Arch Neurol       Date:  1967-03

4.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

Authors:  M E Gurney; H Pu; A Y Chiu; M C Dal Canto; C Y Polchow; D D Alexander; J Caliendo; A Hentati; Y W Kwon; H X Deng
Journal:  Science       Date:  1994-06-17       Impact factor: 47.728

Review 5.  The role of the active site amino acid residues on the catalytic activity of Cu2Zn2SOD.

Authors:  A Scozzafava; M S Viezzoli
Journal:  Mol Chem Neuropathol       Date:  1993 May-Jun

6.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.

Authors:  H X Deng; A Hentati; J A Tainer; Z Iqbal; A Cayabyab; W Y Hung; E D Getzoff; P Hu; B Herzfeldt; R P Roos
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

7.  ALS, SOD and peroxynitrite.

Authors:  J S Beckman; M Carson; C D Smith; W H Koppenol
Journal:  Nature       Date:  1993-08-12       Impact factor: 49.962

8.  Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis.

Authors:  A C Bowling; J B Schulz; R H Brown; M F Beal
Journal:  J Neurochem       Date:  1993-12       Impact factor: 5.372

9.  Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats.

Authors:  M D Linnik; R H Zobrist; M D Hatfield
Journal:  Stroke       Date:  1993-12       Impact factor: 7.914

10.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  96 in total

Review 1.  Progress in the pathogenesis of amyotrophic lateral sclerosis.

Authors:  C E Shaw; A al-Chalabi; N Leigh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

2.  Pathological characterization of astrocytic hyaline inclusions in familial amyotrophic lateral sclerosis.

Authors:  S Kato; H Hayashi; K Nakashima; E Nanba; M Kato; A Hirano; I Nakano; K Asayama; E Ohama
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice.

Authors:  Yi-Bing Zhu; Zu-Hang Sheng
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 4.  Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis.

Authors:  Katharina A Quinlan
Journal:  Integr Comp Biol       Date:  2011-10-11       Impact factor: 3.326

5.  Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration.

Authors:  Y H Gong; A S Parsadanian; A Andreeva; W D Snider; J L Elliott
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

6.  BCL-2 and BAX protect adult mice from lethal Sindbis virus infection but do not protect spinal cord motor neurons or prevent paralysis.

Authors:  Douglas A Kerr; Thomas Larsen; Susan H Cook; Yih-Ru Fannjiang; Eunkyung Choi; Diane E Griffin; J Marie Hardwick; David N Irani
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 7.  The wobbler mouse: a neurodegeneration jigsaw puzzle.

Authors:  Séverine Boillée; Marc Peschanski; Marie-Pierre Junier
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

Review 8.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 9.  Copper chaperones: personal escorts for metal ions.

Authors:  Lori Sturtz Field; Edward Luk; Valeria Cizewski Culotta
Journal:  J Bioenerg Biomembr       Date:  2002-10       Impact factor: 2.945

Review 10.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.